
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI and 2 Center for Health Research, Kaiser Permanente Northwest, Portland, OR
Requests for reprints: Ralph P. Insinga, Department of Health Economic Statistics, Merck Research Laboratories, 10 Sentry Parkway, BL 2-3, Blue Bell, PA 19422. Phone: (484) 344-7847; Fax (484) 344-3855. E-mail: ralph_insinga{at}merck.com
The U.S. Preventive Services Task Force recommends cervical cancer screening begin with the onset of sexual activity and be repeated at least every 3 years until age 65. Previous studies examining the annual utilization and frequency of Pap screening have relied on patient self-report, found to be less reliable than medical records and administrative data. We estimate the age-specific rate and frequency of Pap screening in a U.S. health plan using 19982002 administrative data on 150,052 female enrollees within the Kaiser Permanente Northwest health plan, Portland, OR. We analyze the age-specific rate of cervical and vaginal Pap screening and age-specific proportion of routinely screened women receiving cervical screening at various yearly intervals. Of the enrolled women, 31.2% received a Pap smear in 1998, with utilization highest for ages 2529 (62.4%). Among routinely screened women, 36% were estimated to receive annual cervical smears, versus 22% biennial, 13% triennial, and 29% less frequent screening. Less frequent screening was observed with increasing age. These are the first age-specific estimates of Pap screening frequency and annual utilization in a general healthcare setting, derived from administrative data, rather than self-report. Overall Pap utilization was lower than found in national surveys based on self-report. Despite limited evidence of benefit from more frequent screening, a substantially higher proportion of women was found to receive annual rather than either biennial or triennial screening. Sporadic screening was also more prevalent than expected based on prior self-reported data. Further opportunities exist for improving screening adherence, even within traditionally less vulnerable populations.
This article has been cited by other articles:
![]() |
A. J. Dietrich, J. N. Tobin, A. Cassells, C. M. Robinson, M. Reh, K. A. Romero, A. B. Flood, and M. L. Beach Translation of an Efficacious Cancer-Screening Intervention to Women Enrolled in a Medicaid Managed Care Organization Ann. Fam. Med, July 1, 2007; 5(4): 320 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schiffman, M. J. Khan, D. Solomon, R. Herrero, S. Wacholder, A. Hildesheim, A. C. Rodriguez, M. C. Bratti, C. M. Wheeler, R. D. Burk, et al. A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests J Natl Cancer Inst, January 19, 2005; 97(2): 147 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dandolu and O. Harmanli Cervical Cancer Screening Among Women Without a Cervix JAMA, October 6, 2004; 292(13): 1550 - 1550. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |